MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights "MaxCyte has had a good start to 2025, with core revenue growth in the first quarter driven by continued strength ...